Studies on the binding of 3H-SR121566, an inhibitor of Gp IIb-IIIa activation

Thrombosis and Haemostasis

Volumn 85, Issue 4, 2001, Pages 702-709

  Savi, P ^a   Zamboni, G ^a   Rescanieres O ^a   Herbert, J M ^a  

^a SANOFI   (France)

Author keywords

Anti Gp IIb IIIa; Gp IIb IIIa activation; Human platelets

Indexed keywords

3 [[4 [4 (AMINOIMINOMETHYL)PHENYL] 2 THIAZOLYL](1 CARBOXYMETHYL 4 PIPERIDINYL)AMINO]PROPIONIC ACID; 3 [[4 [4 [AMINO(ETHOXYCARBONYLIMINO)METHYL]PHENYL] 2 THIAZOLYL](1 ETHOXYCARBONYLMETHYL 4 PIPERIDINYL)AMINO]PROPIONIC ACID ETHYL ESTER; 4 [4 [4 (AMINOIMINOMETHYL)PHENYL] 1 PIPERAZINYL] 1 PIPERIDINEACETIC ACID; ABCIXIMAB; AC PENICILAMINE ARGINYLGLYCYLASPARTYLCYSTEINE HYDROXIDE; AGRASTAT; ARGINYLGLYCYLASPARTYLSERINE; DODECAPEPTIDE; FIBRINOGEN; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; N [N [5 [4 (AMINOIMINOMETHYL)PHENYL]PENTANOYL]ASPARTYL]PHENYLALANINE; PEPTIDE DERIVATIVE; THROMBIN RECEPTOR ACTIVATING PEPTIDE; TIROFIBAN; UNCLASSIFIED DRUG; ANTITHROMBOCYTIC AGENT; ARGINYL-GLYCYL-ASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID; BENZYLAMINE DERIVATIVE; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; OLIGOPEPTIDE; PIPERIDINE DERIVATIVE; PROTEIN; THIAZOLE DERIVATIVE; THROMBIN RECEPTOR;

AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; BINDING KINETICS; CONTROLLED STUDY; DRUG BINDING; DRUG BINDING SITE; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INHIBITION KINETICS; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN INTERACTION; PROTEIN STRUCTURE; THROMBOCYTE; THROMBOCYTE ACTIVATION; ANTIBODY SPECIFICITY; BINDING COMPETITION; BINDING SITE; BLOOD CELL; CELL LINE; DRUG ANTAGONISM; METABOLISM; SYNTHESIS; VASCULAR ENDOTHELIUM;

ANTIBODIES, MONOCLONAL; BENZYLAMINES; BINDING SITES; BINDING, COMPETITIVE; BLOOD CELLS; CELL LINE; ENDOTHELIUM, VASCULAR; FIBRINOGEN; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; OLIGOPEPTIDES; ORGAN SPECIFICITY; PIPERIDINES; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROTEIN CONFORMATION; PROTEINS; RECEPTORS, THROMBIN; THIAZOLES;

EID: 0034745015     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615656     Document Type: Article

References (50)

1. Role of fibrinogen α and γ chain sites in platelet aggregation
2. Human platelets possess an inducible and saturable receptor specific for fibrinogen
3. The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets
4. Inhibition of platelet function with synthetic peptides designed to be high-affinity antagonists of fibrinogen binding to platelets
5. Localization of an Arg-Gly-Asp recognition site within an integrin adhesion receptor
6. The ligand binding site of the platelet integrin receptor GPIIb/IIIa is proximal to the second calcium binding domain of its alpha subunit
7. Platelets integrins
8. The role of the RGD peptides and the γ chain peptide of fibrinogen on fibrinogen binding to activated platelets
9. A new model of dual interacting ligand binding sites on integrin aIIb b3
10. Conformational modulation of purified glycoprotein (GP) IIb-IIIa allows proteolytic generation of active fragments from either active or inactive GPIIb-IIIa
11. Role of the γ chain Ala-Gly-Asp-Val and a α chain Arg-Gly-Asp-Ser sites of fibrinogen in coaggregation of platelets and fibrinogen-coated beads
12. Reconstitution of the purified platelet fibrinogen receptor
13. Platelet GPIIb-IIIa blockers
14. Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use?
15. New orally active fibrinogen receptor (GpIIb-IIIa) antagonists: Identification of ethyl 3-[N-[4-[4-[amino[(ethoxycarbonyl)imino]methyl]-phenyl]-1,3-thiazol-2-yl]-N-[1-[ (ethoxycarbonyl)methyl]piperid-4-yl]amino]-propionate (SR121787) as a potent and long-acting antithrombotic agent
16. SR121787, a new orally active fibrinogen receptor antagonist
17. Interspecies comparison of the antiplatelet, antithrombotic and haemorrhagic effects of SR121566A, a novel nonpeptide GpIIb/IIIa antagonist
18. Binding of [3H]-2-methylthio ADP to rat platelets: Effect of clopidogrel and ticlopidine
19. "Bridged" Peptide of fibrinogen binds to platelets activated by RGD peptide as well as by ADP
20. A mathematical approach to receptor characterization
21. The attractions of proteins for small molecules and ions
22. Relationship between the inhibition constant (Ki) and the concentration of inhibitors which causes 50% inhibition (IC50) of an enzymatic reaction
23. Influence of stereochemistry of the sequence Arg-Gly-Asp-Xaa on binding specificity in cell adhesion
24. Induction of the fibrinogen receptor on human platelets by intracellular mediators
25. Reversible conformational changes induced in glycoprotein IIb-IIIa by a potent and selective peptidomimetic inhibitor
26. Distribution of ligand-occupied alpha IIb beta 3 in resting and activated human platelets determined by expression of a novel class of ligand-induced binding site recognized by monoclonal antibody AP6
27. Resting platelets contain a substantial centrally located pool of glycoprotein IIb-IIIa complex which may be accessible to some but not other extracellular proteins
28. Labeling of the internal pool of GP IIb-IIIa in platelets by c7E3 Fab fragments (abciximab): Flow and endocytic mechanisms contribute to the transport
29. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets
30. Interaction of fibrinogen with its platelet receptor as part of a multistep reaction in ADP-induced platelet aggregation
31. Quantitation of membrane glycoprotein IIIa on intact human platelets using the monoclonal antibody, AP-3
32. The Arg-Gly-Asp (RGD) recognition site of platelet glycoprotein IIb-IIIa on nonactivated platelets is accessible to high-affinity macromolecules
33. Localization of internal pools of membrane glycoproteins involved in platelet adhesive responses
34. Increased surface expression of the membrane glycoprotein IIb/IIIa complex induced by platelet activation. Relationship to the binding of fibrinogen and platelet aggregation
35. Evidence that arginyl-glycyl-aspartate peptides and fibrinogen γ chain peptides share a common binding site on platelets
36. Amino acid sequences in fibrinogen mediating its interaction with its platelet receptor, Gp IIb-IIIa
37. The interaction of disagregin with the platelet fibrinogen receptor, glycoprotein IIb-IIIa
38. 3H]-SB214857 to purified integrin αIIbβIII: Evidence for a common binding site for cyclic arginyl-glycinyl-aspartic acid peptides and nonpeptides
39. Interaction of fibrinogen with its platelet receptor
40. Ligands "activate" integrin αIIbβ3 (platelet GP IIb IIIa)
41. RGD induces conformational transition in purified platelet integrin GPIIb-IIIa-SDS system yielding multiple binding states for fibrinogen γ-chain C-terminal peptide
42. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (αIIbβ3) inhibitors
43. GPIIb/IIIa antagonists: Pathophysiologic and therapeutic insights from studies of c7E3 Fab
44. Platelet γ granules
45. Irreversible platelet fibrinogen interactions occur independently of fibrinogen alpha chain degradation and are not mediated by intact platelet membrane glycoprotein IIb-IIIa complexes
46. Internalization of bound fibrinogen modulates platelet aggregation
47. Interaction of thrombospondin with resting and stimulated human platelets
48. Thrombospondin binding to specific sequences within the Aα- and Bβ-chains of fibrinogen
49. Determination of kinetic constants for the interaction between the platelet glycoprotein IIb-IIIa and fibrinogen by means of surface plasmon resonance
50. Two-step binding mechanism of fibrinogen to αIIbβ3 integrin reconstituted into planar lipid balayers